Cargando…

A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics

Physiological changes in pregnancy, including changes in body composition and metabolic enzyme activity, can alter drug pharmacokinetics. A semi-mechanistic metabolism model was developed to describe the pharmacokinetics of two cytochrome P450 3A (CYP3A) substrates, midazolam and nifedipine, in obst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quinney, S K, Mohamed, A N, Hebert, M F, Haas, D M, Clark, S, Umans, J G, Caritis, S N, Li, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603475/ https://www.ncbi.nlm.nih.gov/pubmed/23835882 http://dx.doi.org/10.1038/psp.2012.5

Ejemplares similares

Pregnancy related hormones increase CYP3A mediated buprenorphine metabolism in human hepatocytes: a comparison to CYP3A substrates nifedipine and midazolam
por: Fashe, Muluneh M., et al.
Publicado: (2023)

The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery
por: Brill, Margreke J., et al.
Publicado: (2015)

Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
por: Wiebe, Sabrina T., et al.
Publicado: (2020)

Integration of In Vitro Binding Mechanism Into the Semiphysiologically Based Pharmacokinetic Interaction Model Between Ketoconazole and Midazolam
por: Quinney, Sara K., et al.
Publicado: (2013)

Population Pharmacokinetic Modelling for Nifedipine to Evaluate the Effect of Parathyroid Hormone on CYP3A in Patients with Chronic Kidney Disease
por: Fu, Chengxiao, et al.
Publicado: (2022)

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children
por: Brussee, Janneke M., et al.
Publicado: (2019)

Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats
por: Nontakham, Jannarin, et al.
Publicado: (2022)

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients
por: Brill, MJE, et al.
Publicado: (2015)

Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)
por: Nebot, Noelia, et al.
Publicado: (2021)

Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats
por: Tian, Xin, et al.
Publicado: (2013)

An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors
por: Shumaker, Robert, et al.
Publicado: (2020)

Contribution of Baicalin on the Plasma Protein Binding Displacement and CYP3A Activity Inhibition to the Pharmacokinetic Changes of Nifedipine in Rats In Vivo and In Vitro
por: Cheng, Zhen-Yu, et al.
Publicado: (2014)

Effect of Gut Microbiota on the Pharmacokinetics of Nifedipine in Spontaneously Hypertensive Rats
por: Zhou, Rong, et al.
Publicado: (2023)

Application of Semi-Mechanistic Pharmacokinetic and Pharmacodynamic Model in Antimicrobial Resistance
por: Mi, Kun, et al.
Publicado: (2022)

Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy
por: Koren, Gideon, et al.
Publicado: (2016)

Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial
por: Koren, Gideon, et al.
Publicado: (2015)

Amenamevir: Studies of Potential CYP3A‐Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers
por: Adeloye, Temitope, et al.
Publicado: (2018)

The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam
por: Wiesinger, Herbert, et al.
Publicado: (2020)

Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review
por: van de Vusse, Dylan, et al.
Publicado: (2022)

Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
por: Brussee, Janneke M., et al.
Publicado: (2018)

Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors
por: Zhu, Yun-Ting, et al.
Publicado: (2020)

Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys
por: Lu, Dan, et al.
Publicado: (2014)

Magnesium Sulfate in combination with Nifedipine in the treatment of Pregnancy-Induced Hypertension
por: Xiang, Cuiping, et al.
Publicado: (2020)

Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers
por: Brill, Margreke J. E., et al.
Publicado: (2014)

Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
por: Becker, Corina, et al.
Publicado: (2013)

Pharmacokinetic–Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
por: Flores-Pérez, Carmen, et al.
Publicado: (2023)

Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions
por: Muchohi, Simon N, et al.
Publicado: (2008)

Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib
por: Liu, Hongrui, et al.
Publicado: (2022)

Effects of tomato juice on the pharmacokinetics of CYP3A4-substrate drugs
por: Ohkubo, Atsuko, et al.
Publicado: (2017)

A cocktail probe approach to evaluate the effect of hormones on the expression and activity of CYP enzymes in human hepatocytes with conditions simulating late stage of pregnancy
por: Alshabi, Ali, et al.
Publicado: (2023)

Inhibition of CYP3A-mediated Midazolam Metabolism by Kaempferia Parviflora
por: Kashiwabuchi, Yumika, et al.
Publicado: (2022)

Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion
por: Nassar, Yomna M., et al.
Publicado: (2022)

Evidence of CYP3A Allosterism In Vivo: Analysis of Fluconazole and Midazolam Interaction
por: Yang, Jing, et al.
Publicado: (2011)

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
por: Biliouris, Konstantinos, et al.
Publicado: (2018)

Efficacy of resveratrol to supplement oral nifedipine treatment in pregnancy-induced preeclampsia
por: Ding, Jian, et al.
Publicado: (2017)

Nifedipine plus Systematic Nursing on Pregnancy Outcomes in Patients with Gestational Hypertension
por: Ma, Yan, et al.
Publicado: (2022)

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2020)

Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease
por: de Castro-Suárez, Niurys, et al.
Publicado: (2020)

Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants
por: Hoch, Matthias, et al.
Publicado: (2022)

Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
por: Vossen, Michaela, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_8j28i87fflb6n15ndue65fc2m1